Clinical trials: Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT03026166
- Testing
- Ipilimumab, Nivolumab, Rovalpituzumab tesirine
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
Extensive-stage Small-cell Lung Cancer
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with…
- Trial name
- NCT07502300
- Testing
- BL-B01D1, Tislelizumab, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 562 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Small Cell Lung Carcinoma
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung…
- Trial name
- NCT00143455
- Testing
- Etoposide + cisplatin, Irinotecan + cisplatin
- Where
- 67 sites in Austria, Belgium and 11 more
- Volunteers
- 485 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and…
- Trial name
- ALISCA-Lung1 (NCT06095505)
- Testing
- Alisertib
- Where
- 30 sites in United States
- Volunteers
- 120 people
- Sponsor
- Puma Biotechnology, Inc.
Small Cell Lung Cancer Extensive Stage
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06954246
- Testing
- MHB088C for Injection, Topotecan, Irinotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus…
- Trial name
- NCT00363415
- Testing
- pemetrexed, etoposide, carboplatin
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 908 people
- Sponsor
- Eli Lilly and Company
SCLC
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT05844150
- Testing
- PM8002, Platinum, Etoposide
- Where
- 17 sites in China
- Volunteers
- 50 people
- Sponsor
- Biotheus Inc.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung…
- Trial name
- EVOKE-SCLC-04 (NCT06801834)
- Testing
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only)
- Where
- 219 sites in United States, Argentina and 21 more
- Volunteers
- 695 people
- Sponsor
- Gilead Sciences
Carcinoma, Small Cell
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
- Trial name
- NCT00537511
- Testing
- Pomalidomide, Cisplatin, Etoposide
- Where
- 6 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Celgene
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung…
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
- Trial name
- NCT07625644
- Testing
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 550 people
- Sponsor
- SystImmune Inc.
Extensive Stage Small Cell Lung Cancer
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248.
- Trial name
- DeLLphi-311 (NCT07037758)
- Testing
- Tarlatamab, AB248
- Where
- 19 sites in United States, South Korea and 1 more
- Volunteers
- 380 people
- Sponsor
- Amgen
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
- Trial name
- DART-NK-SCLC (NCT07480213)
- Testing
- EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Extensive Stage Small Cell Lung Carcinoma
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)
- Trial name
- NCT01439568
- Testing
- LY2510924, Carboplatin, Etoposide
- Where
- 15 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage…
- Trial name
- NCT07892625
- Testing
- HS-20093 for Injection, ZG006, Adebrelimab Injection
- Volunteers
- 338 people
- Sponsor
- Hansoh BioMedical R&D Company
Small Cell Lung Cancer
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
- Trial name
- NCT01237678
- Testing
- IMGN901, Carboplatin and Etoposide
- Where
- 48 sites in United States, Canada and 2 more
- Volunteers
- 181 people
- Sponsor
- ImmunoGen, Inc.
Extensive-stage Small Cell Lung Cancer
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
- Trial name
- NCT00682981
- Testing
- Obatoclax, Carboplatin/etoposide
- Where
- 75 sites in United States, Bulgaria and 8 more
- Volunteers
- 218 people
- Sponsor
- Gemin X
Small Cell Lung Cancer
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.
- Trial name
- NCT03116971
- Testing
- M3814, Cisplatin, Etoposide
- Where
- 80 sites in United States, Belgium and 11 more
- Volunteers
- 2 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.
- Conditions
- Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05882058
- Testing
- BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Extensive-Stage Small Cell Lung Cancer
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT07796100
- Testing
- ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
- Volunteers
- 530 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Small Cell Lung Cancer
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy.
- Trial name
- NCT00043927
- Testing
- topotecan/cisplatin, etoposide/cisplatin
- Where
- 176 sites in United States, Austria and 32 more
- Volunteers
- 760 people
- Sponsor
- GlaxoSmithKline